Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

By Michael E. Weinblatt, E. Keystone, D. Furst, L. Moreland, M. Weisman, C. Birbara, L. Teoh, S. Fischkoff, E. Chartash. Arthritis & Rheumatism, 2003

1,909 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. (2006, background): “The differences in terms of clinical efficacy between low-dose anti-TNF antibody treatment (adalimumab, 20 mg every other week, or infliximab, 1 mg/kg every 4 weeks) and the currently recommended substantially higher doses were marginal and statistically not significant in published clinical trials.”
Matrix metalloproteinases: role in arthritis. (2006, background): “Finally, combination treatment of MTX with adalimumab, another anti-TNF-alpha monoclonal antibody, significantly decreased the time to reach a 20% improvement in disease activity (ACR20), and led to significant decreases in the serum levels of proMMP-1 and proMMP-3 (142).”
Therapeutic antibodies for autoimmunity and inflammation (2010, background): “Adalimumab, a phage-derived human antibody, has an incidence of 12% neutralizing HAHAs in patients with rheumatoid arthritis receiving monotherapy that is decreased to ∼1% in patients also treated with the immunosuppressant methotrexat”